
Annual report 2025
added 03-03-2026
Evolus EPS Ratio 2011-2026 | EOLS
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Evolus
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.8 | -0.81 | -1.08 | -1.33 | -0.94 | -4.83 | -3.19 | -1.92 | -0.27 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -0.27 | -4.83 | -1.69 |
Quarterly EPS Ratio Evolus
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.24 | -0.27 | -0.3 | - | -0.3 | -0.18 | -0.22 | - | -0.3 | -0.32 | -0.26 | - | -0.36 | -0.42 | -0.31 | - | -0.35 | -0.31 | 0.17 | - | -0.34 | -0.63 | -0.59 | - | -0.98 | -1.37 | -0.4 | - | -0.48 | -0.69 | -0.3 | - | -0.16 | -0.14 | -0.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.17 | -1.37 | -0.381 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Drug manufacturers industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
AcelRx Pharmaceuticals
ACRX
|
-0.34 | - | 7.5 % | $ 6.35 M | ||
|
Agile Therapeutics
AGRX
|
-6.71 | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
-0.84 | - | - | $ 142 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
-0.18 | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
-1.61 | - | - | $ 754 M | ||
|
DURECT Corporation
DRRX
|
-1.05 | - | - | $ 50.1 M | ||
|
Eagle Pharmaceuticals
EGRX
|
2.76 | - | -39.89 % | $ 27.7 M | ||
|
Endo International plc
ENDP
|
-10.4 | - | - | $ 28.9 M | ||
|
Catalent
CTLT
|
-5.76 | - | - | $ 11.5 B | ||
|
Harrow Health
HROW
|
-0.14 | $ 41.51 | 2.41 % | $ 1.53 B | ||
|
Athenex
ATNX
|
-15.8 | - | -23.39 % | $ 1.76 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
-0.14 | $ 4.14 | -1.19 % | $ 58.2 M | ||
|
Avadel Pharmaceuticals plc
AVDL
|
-0.51 | - | - | $ 2.06 B | ||
|
Pacira BioSciences
PCRX
|
-2.15 | $ 25.04 | -1.77 % | $ 1.16 B | ||
|
Jupiter Wellness
JUPW
|
-17 | - | - | $ 33.6 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
-9.66 | - | -0.1 % | $ 2.03 B | ||
|
HEXO Corp.
HEXO
|
-0.89 | - | 2.45 % | $ 38.1 M | ||
|
Solid Biosciences
SLDB
|
-1.99 | $ 7.13 | -1.86 % | $ 624 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
-2.79 | $ 1.15 | 4.55 % | $ 1.43 M | ||
|
Evoke Pharma
EVOK
|
-2.33 | - | - | $ 36.6 M | ||
|
Bausch Health Companies
BHC
|
-1.62 | $ 5.57 | -2.62 % | $ 2.03 B | ||
|
Tilray
TLRY
|
-2.35 | $ 6.13 | -1.76 % | $ 3.79 B | ||
|
Canopy Growth Corporation
CGC
|
-5.56 | $ 1.13 | 1.35 % | $ 122 M | ||
|
Veru
VERU
|
-0.28 | $ 2.26 | 0.44 % | $ 305 M | ||
|
Aurora Cannabis
ACB
|
-4.1 | $ 3.46 | 0.58 % | $ 86.3 M | ||
|
Lannett Company
LCI
|
-5.74 | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
-0.51 | $ 1.43 | 1.06 % | $ 402 M | ||
|
Sundial Growers
SNDL
|
-1.1 | $ 1.42 | 4.04 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
-14.8 | $ 8.32 | 1.09 % | $ 426 M | ||
|
Organogenesis Holdings
ORGO
|
-0.01 | $ 2.44 | 3.83 % | $ 321 M | ||
|
Neoleukin Therapeutics
NLTX
|
-4.24 | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
-1.79 | $ 0.82 | -5.79 % | $ 3.54 M | ||
|
ProPhase Labs
PRPH
|
1.17 | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
-1.49 | - | - | $ 1.42 B | ||
|
Assertio Holdings
ASRT
|
-4.74 | $ 18.42 | -0.08 % | $ 118 M | ||
|
PetIQ
PETQ
|
0.07 | - | 1.64 % | $ 400 M | ||
|
Relmada Therapeutics
RLMD
|
-1.45 | $ 7.68 | 2.13 % | $ 303 M | ||
|
Recro Pharma
REPH
|
-0.14 | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
-0.32 | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
-0.17 | $ 0.98 | 5.87 % | $ 48.9 M | ||
|
PLx Pharma
PLXP
|
-2.06 | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
0.05 | $ 15.03 | 0.6 % | $ 18 B | ||
|
Zomedica Corp.
ZOM
|
-0.08 | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
-0.82 | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
-0.15 | $ 0.87 | -1.19 % | $ 31.3 M | ||
|
Tricida
TCDA
|
-3.44 | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
-0.74 | $ 0.57 | 5.35 % | $ 2.45 M | ||
|
TherapeuticsMD
TXMD
|
-0.05 | $ 2.05 | 0.25 % | $ 23.7 M |